Bristlecone Advisors, LLC
- SEC CIK
- 0001671716
- Latest filing
- Oct 24, 2025
VRTX holding history
Vertex Pharmaceuticals Inc in every 13F filed by Bristlecone Advisors, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VRTX overviewAll 13F holders of VRTXFull Q3 2025 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −2,250−100.0% | Sold out | Holders |
| Q1 2025 | 2,250 | $1.09M | 0.1% | +100+4.7% | Added | Holders |
| Q4 2024 | 2,150 | $865.8K | 0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 2,150 | $999.9K | 0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 2,150 | $1.01M | 0.1% | −15−0.7% | Reduced | Holders |
| Q1 2024 | 2,165 | $905.0K | 0.1% | +115+5.6% | Added | Holders |
| Q4 2023 | 2,050 | $834.1K | 0.1% | +5+0.2% | Added | Holders |
| Q3 2023 | 2,045 | $711.1K | 0.1% | −56−2.7% | Reduced | Holders |
| Q2 2023 | 2,101 | $739.4K | 0.1% | −58−2.7% | Reduced | Holders |
| Q1 2023 | 2,159 | $680.2K | 0.1% | −326−13.1% | Reduced | Holders |
| Q4 2022 | 2,485 | $717.6K | 0.1% | −51−2.0% | Reduced | Holders |
| Q3 2022 | 2,536 | $734.0K | 0.1% | −29−1.1% | Reduced | Holders |
| Q2 2022 | 2,565 | $723.0K | 0.1% | +302+13.3% | Added | Holders |
| Q1 2022 | 2,263 | $591.0K | 0.1% | +24+1.1% | Added | Holders |
| Q4 2021 | 2,239 | $492.0K | 0.1% | +274+13.9% | Added | Holders |
| Q3 2021 | 1,965 | $356.0K | <0.1% | +410+26.4% | Added | Holders |
| Q2 2021 | 1,555 | $314.0K | <0.1% | +21+1.4% | Added | Holders |
| Q1 2021 | 1,534 | $330.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.